Bli medlem
Bli medlem

Du är här


EQT AB: EQT Mid Market invests in Fertin Pharma A/S

· EQT Mid Market acquires Fertin Pharma, the world's largest
independent developer and manufacturer of medicated chewing gum

· The founding Bagger-Sørensen family will reinvest and enter into a
partnership with EQT Mid Market with the view to further develop and
accelerate the growth of Fertin Pharma

· The management team of Fertin Pharma, led by CEO Søren Birn, will
remain with the Company and invest alongside the Bagger-Sørensen
family and EQT Mid Market

EQT Mid Market has agreed to acquire Fertin Pharma ("Fertin Pharma" or
the "Company") from the Bagger-Sørensen family. The Bagger-Sørensen
family will reinvest part of their proceeds and will following the
transaction own 30% of the Company.

The Company is the leading independent B2B developer and manufacturer
of medicated chewing gum, primarily within Nicotine Replacement
Therapy ("NRT"), a pharmaceutical product used for withdrawal
management in the process of tobacco cessation. Furthermore, Fertin
develops pharmaceutical chewing gum with different APIs (MediChew)
and nutraceutical chewing gum products (Nutraceuticals).

Rikke Kjær Nielsen, Director at EQT Partners and Investment Advisor to
EQT Mid Market, said: "We are truly impressed by Fertin Pharma's
strong management team and its unparalleled market position based on
a unique combination of more than 100 years of chewing gum heritage,
profound nicotine knowledge and strong pharma manufacturing
capabilities. Fertin is a global market leader within NRT gum with a
strong financial track record operating in one of EQT's core sectors
and core geographies. As such we see an excellent match with EQT,
which is further underpinned by the EQT track record in healthcare
investments and experience in supporting companies to drive growth
across different avenues. We are therefore extremely pleased about
the partnership with the founding family to jointly develop Fertin
into an even stronger company".

Søren Birn, CEO of Fertin Pharma, said: "Fertin has developed a global
stronghold with its leading NRT gum product portfolio and realized
above market growth for several years.We are very pleased to have EQT
as our new majority owner and partner in this exciting phase for
Fertin. We share the same vision and ambitions for Fertin's great
potential. Under the new partnership, we look very much forward to
continue growing the core business while exploring new avenues of
growth for the Company".

Steen and Claus Bagger-Sørensen, main shareholders of Fertin Pharma,
said: "We are pleased to have EQT as the new majority owner of
Fertin, and we believe they are a great fit with Fertin, both in
terms of core values, visions and long-term ambitions for the
Company. Furthermore, we are excited about entering a partnership
with them, and we look forward to working alongside EQT and
contributing knowledge, experience and history".

Financial terms of the transaction are not disclosed.


Rikke Kjær Nielsen at EQT Partners, Investment Advisor to EQT Mid
Market, +45 4021 1216

Kerstin Danasten, EQT Press Officer, +46 8 506 55 334

About the Bagger-Sørensen family

The Bagger-Sørensen family founded Vejle Caramel og Tablet Fabrik in
1915 and launched the Dandy chewing gum brand in 1939. In 1978, the
Swedish company Fertin, known for their V6 chewing gum, was acquired
by the Bagger-Sørensen Group. Following the acquisition the company
was renamed Fertin Pharma and in 2000 Fertin Pharma launched the
world's first coated nicotine gum. Today, the family brothers Steen
and Claus Bagger-Sørensen, along with the family fund, comprise the
owners of Fertin Pharma prior to the transaction.

About EQT

EQT is a leading alternative investments firm with approximately EUR
31 billion in raised capital. EQT Funds have portfolio companies in
Europe, Asia and the US with total sales of more than EUR 15 billion
and approximately 100,000 employees. EQT works with portfolio
companies to achieve sustainable growth, operational excellence and
market leadership.

More info:

About Fertin Pharma

Fertin Pharma A/S is a family-owned company based in Vejle, Denmark,
with additional facilities in India. Fertin is the world's leading
B2B developer/manufacturer of medicated chewing gum, specialising in
Nicotine Replacement Therapy gum. Fertin has 715 employees and an
estimated 2016 revenue of DKK 851m and EBITDA of DKK 250m.

More info:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.